After passing on M&A offers, Abcuro raises $200M in bid to become commercial drugmaker
After quickly enrolling its pivotal trial and recruiting more patients with a rare muscle disease than anticipated, Abcuro went to its board to explore a $60 million to $80 million fundraise. That initial ask in ...
After quickly enrolling its pivotal trial and recruiting more patients with a rare muscle disease than anticipated, Abcuro went to its board to explore a $60 million to $80 million fundraise.
That initial ask in ...
